TABLE 2.

Study drug dosing and administration^a

Patient variable	Value for patients treated with:		P valueb
	CST (n = 4,817)	CST-MIN (n = 93)
No. of days on MIN
Mean ± SD	NA	10.1 ± 7.6
Median (Q1, Q3)	NA	8 (5, 14)
Total no. of vials of MIN
Mean ± SD	NA	21.5 ± 18.6
Median (Q1, Q3)	NA	16 (10, 29)
Daily no. of vials of MIN, % of patients
2 vials	NA	88.2
3 vials	NA	8.6
4 vials	NA	3.2
No. of days on CST
Mean ± SD	10.0 ± 8.3	12.7 ± 10.4	0.009
Median (Q1, Q3)	8 (5, 12)	9 (6, 15)
Total no. of vials of CST
Mean ± SD	21.4 ± 23.2	22.8 ± 18.9	0.428
Median (Q1, Q3)	15 (9, 27)	17 (9, 30)
Daily no. of vials of CST,c % of patients
1 vial	22.3	35.5	0.058
2 vials	54.1	51.6
3 vials	15.6	9.7
≥4 vials	8.0	3.2
No. of days of treatment overlap
Mean ± SD	NA	7.2 ± 4.3
Median (Q1, Q3)	NA	6 (4, 9)
No. of days from admission to initiation of study drug
Mean ± SD	14.6 ± 20.0	14.3 ± 23.2	0.069
Median (Q1, Q3)	8 (4, 18)	5 (2, 17)
Sequence of CST-MIN administration, % of patients
MIN initiated prior to CST	NA	19.4
MIN and CST initiated on the same day	NA	35.5
MIN initiated after CST	NA	45.2

^aAbbreviations: CST, colistin; CST-MIN, colistin-minocycline; MIN, minocycline; NA, not applicable.

^bP values in bold indicate a significance difference.

^cOne vial of colistin = 150 mg colistin-based activity (CBA).